Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP410470.RA0Tgo59W_Q2qKrJT5mJq-6pEXE9-r3jV96oDz8vge5jU130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP410470.RA0Tgo59W_Q2qKrJT5mJq-6pEXE9-r3jV96oDz8vge5jU130_assertion type Assertion NP410470.RA0Tgo59W_Q2qKrJT5mJq-6pEXE9-r3jV96oDz8vge5jU130_head.
- NP410470.RA0Tgo59W_Q2qKrJT5mJq-6pEXE9-r3jV96oDz8vge5jU130_assertion description "[We also describe the recent development and validation of the most studied mucins (MUC1 and MUC16), ErbB-2 (Her2/neu) and folate binding protein as target-based immunotherapy of ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP410470.RA0Tgo59W_Q2qKrJT5mJq-6pEXE9-r3jV96oDz8vge5jU130_provenance.
- NP410470.RA0Tgo59W_Q2qKrJT5mJq-6pEXE9-r3jV96oDz8vge5jU130_assertion evidence source_evidence_literature NP410470.RA0Tgo59W_Q2qKrJT5mJq-6pEXE9-r3jV96oDz8vge5jU130_provenance.
- NP410470.RA0Tgo59W_Q2qKrJT5mJq-6pEXE9-r3jV96oDz8vge5jU130_assertion SIO_000772 14755889 NP410470.RA0Tgo59W_Q2qKrJT5mJq-6pEXE9-r3jV96oDz8vge5jU130_provenance.
- NP410470.RA0Tgo59W_Q2qKrJT5mJq-6pEXE9-r3jV96oDz8vge5jU130_assertion wasDerivedFrom befree-20150227 NP410470.RA0Tgo59W_Q2qKrJT5mJq-6pEXE9-r3jV96oDz8vge5jU130_provenance.
- NP410470.RA0Tgo59W_Q2qKrJT5mJq-6pEXE9-r3jV96oDz8vge5jU130_assertion wasGeneratedBy ECO_0000203 NP410470.RA0Tgo59W_Q2qKrJT5mJq-6pEXE9-r3jV96oDz8vge5jU130_provenance.